Hangzhou Tigermed Consulting Co., Ltd
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HNGZY research report →
Price Chart
About the company
Hangzhou Tigermed Consulting Co. , Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc.
- CEO
- Xiao Chun Cao
- IPO
- 2022
- Employees
- 11,130
- HQ
- Hangzhou, TJ, CN
Get TickerSpark's AI analysis on HNGZY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $6.86B
- P/E
- 689.75
- PEG
- -9.02
- P/S
- 5.59
- P/B
- 2.37
- EV/EBITDA
- 24.86
- Div Yield
- 0.23%
- Gross Margin
- 25.85%
- Op Margin
- 16.39%
- Net Margin
- 1.25%
- ROE
- 0.44%
- ROIC
- 2.49%
Latest fiscal year · YoY change
- Revenue
- $6.83B+3.5%
- Gross Profit
- $1.87B-16.5%
- Op Income
- $1.01B
- Net Income
- $887.89M+119.2%
- EPS
- $1.04+121.3%
- OCF Growth
- +1.9%
- FCF Growth
- +22.0%
- 52W High
- $4.45
- 52W Low
- $4.00
- 50D MA
- $4.45
- 200D MA
- $4.17
- Beta
- 0.41
- RSI (14)
- 100
- Avg Volume
- 164
No earnings-call transcripts are available for HNGZY yet.
- Free Float
- 40.6%
- Shares Outstanding
- 1.54B
- Float Shares
- 626.20M
Our HNGZY coverage
Recent articles, reports, and earnings notes.
No research on HNGZY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HNGZY report →